Teva Lowers Forecast As Q3 Revenues Decline Amid Growing Generic Competition
But Opioid Crisis Settlement On Track
The Israeli firm’s third-quarter revenues and profits decreased as its product sales dipped due to alternative options and generic competition leading it to lower its full-year guidance, but its opioid crisis financial settlement remains on track.
